MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial

Menopause. 2009 May-Jun;16(3):458-65. doi: 10.1097/gme.0b013e31818e64dd.

Abstract

Objective: To determine the optimal dose, safety, and efficacy of an estrogen receptor beta selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes.

Methods: A randomized, blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks.

Results: The effects of 5 g/day of MF101 did not differ from those of placebo. After 12 weeks, the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9% greater than that in the placebo group (P = 0.15), the median percent decrease was 11.7% greater than that in the placebo group (P = 0.05), and the proportion of women with at least a 50% reduction in hot flushes was 16.2% greater than that in the placebo group (P = 0.03).

Conclusions: Treatment with 10 g/day of MF101 reduces the frequency of hot flushes. Trials with higher doses are planned.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Endometrium / drug effects
  • Endometrium / pathology
  • Female
  • Hot Flashes / drug therapy*
  • Humans
  • Menopause
  • Metrorrhagia / chemically induced
  • Middle Aged
  • Plant Extracts / administration & dosage*
  • Plant Extracts / adverse effects
  • Selective Estrogen Receptor Modulators / administration & dosage*
  • Selective Estrogen Receptor Modulators / adverse effects

Substances

  • MF101 extract
  • Plant Extracts
  • Selective Estrogen Receptor Modulators